A newly published report from the Government Accountability Office highlights significant procedural gaps in how federal agencies evaluate substances and formulate scheduling recommendations under the Controlled Substances Act. Released amid the ongoing administrative review to move cannabis from Schedule I to Schedule III, the watchdog agency emphasizes the need for transparent, standardized evaluation criteria across federal health and law enforcement departments. The findings arrive as the Drug Enforcement Administration continues its deliberation process, facing intense scrutiny from lawmakers, industry stakeholders, and public health advocates regarding the scientific basis and timeline of federal cannabis reform.
While the GAO report does not explicitly mandate specific outcomes for the current marijuana review, it scrutinizes the mechanics of federal drug policy—pointing to inconsistencies that could influence how future reclassification decisions are administered and justified. For cannabis operators navigating a complex multi-state regulatory environment, federal oversight of the scheduling process remains a central variable in long-term operational planning, banking access, and interstate commerce projections. As federal agencies respond to the watchdog recommendations, compliance professionals are monitoring whether administrative adjustments will accelerate or complicate the broader federal reform timeline.